InsiderTrades

Form 4 for VRTX Vertex Pharmaceuticals

Accepted 2024-02-14 00:00:00 ET · period of report 2024-02-12 · accession 0000875320-24-000059 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
M 2024-02-14 2024-02-12+ VRTX LEIDEN JEFFREY M Executive COB, Dir S - Sale $419.42 -3,393 28.3K -11% -$1.42M

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-02-12 S D 647 $420.39 27,644 D — — (F2) Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. (F4) Open market sales reported on this line occurred at a weighted average price of $420.39 (range $420.21 to $420.94).
2 Common Common Stock 2024-02-13 S D 737 $419.13 26,907 D — — (F5) Open market sales reported on this line occurred at a weighted average price of $419.13 (range $419.00 to $419.37). (F2) Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
3 Common Common Stock 2024-02-12 S D 2,009 $419.22 28,291 D — — (F2) Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. (F3) Open market sales reported on this line occurred at a weighted average price of $419.22 (range $419.00 to $419.71).